Tissue-specific deletion of Crry from mouse proximal tubular epithelial cells increases susceptibility to renal ischemia-reperfusion injury

Kidney International

Volumn 86, Issue 4, 2014, Pages 726-737

  Miao, Jing ^a   Lesher, Allison M ^a   Miwa, Takashi ^a   Sato, Sayaka ^a   Gullipalli, Damodar ^a   Song, Wen Chao ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

complement; inflammation; ischemia reperfusion

Indexed keywords

CELL SURFACE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPLEMENT RECEPTOR 1 RELATED PROTEIN; MEGALIN; MONOCLONAL ANTIBODY; NITROGEN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROPERDIN; UNCLASSIFIED DRUG; UREA; COMPLEMENT RECEPTOR; CRRY PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; CRRY GENE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; EXON; GENE DELETION; GLOMERULOPATHY; IMMUNOFLUORESCENCE TEST; INFLAMMATORY INFILTRATE; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY PROXIMAL TUBULE; KNOCKOUT GENE; MONONUCLEAR PHAGOCYTE; MOUSE; NICK END LABELING; NONHUMAN; PHENOTYPE; PHENOTYPIC VARIATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; RISK FACTOR; UREA NITROGEN BLOOD LEVEL; ANIMAL; DRUG EFFECTS; GENE INACTIVATION; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHAGOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOOD UREA NITROGEN; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C5; EPITHELIAL CELLS; GENE KNOCKOUT TECHNIQUES; GENETIC PREDISPOSITION TO DISEASE; KIDNEY TUBULES, PROXIMAL; MICE; MICE, KNOCKOUT; PHAGOCYTES; PROPERDIN; RECEPTORS, COMPLEMENT; REPERFUSION INJURY;

EID: 84926147452     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.103     Document Type: Article

References (47)

1. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20: 34-50.
2. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058-1066.
3. Lesher AM, Song WC. Review: complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) 2010; 15: 663-675.
4. Sacks S, Zhou W. New boundaries for complement in renal disease. J Am Soc Nephrol 2008; 19: 1865-1869.
5. Brown KM, Sacks SH, Sheerin NS. Mechanisms of disease: the complement system in renal injury-new ways of looking at an old foe. Nat Clin Pract Nephrol 2007; 3: 277-286.
6. Pickering M, Cook HT. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens 2011; 20: 271-277.
7. Thurman JM. Triggers of inflammation after renal ischemia/reperfusion. Clin Immunol 2007; 123: 7-13.
8. Lien YH, Lai LW, Silva AL. Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice. Life Sci 2003; 74: 543-552.
9. Arumugam TV, Shiels IA, Woodruff TM et al. The role of the complement system in ischemia-reperfusion injury. Shock 2004; 21: 401-409.
10. Chowdhury P, Zhou W, Sacks SH. Complement in renal transplantation. Nephron Clin Pract 2003; 95: c3-c8.
11. Puri TS, Quigg RJ. The many effects of complement C3-and C5-binding proteins in renal injury. Semin Nephrol 2007; 27: 321-337.
12. Ichida S, Yuzawa Y, Okada H et al. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 1994; 46: 89-96.
13. Seya T, Turner JR, Atkinson JP. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med 1986; 163: 837-855.
14. Kim DD, Song WC. Membrane complement regulatory proteins. Clin Immunol 2006; 118: 127-136.
15. Miwa T, Song WC. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int Immunopharmacol 2001; 1: 445-459.
16. Mizuno M, Harris CL, Suzuki N et al. Expression of CD46 in developing rat spermatozoa: ultrastructural localization and utility as a marker of the various stages of the seminiferous tubuli. Biol Reprod 2005; 72: 908-915.
17. Mizuno M, Harris CL, Johnson PM et al. Rat membrane cofactor protein (MCP; CD46) is expressed only in the acrosome of developing and mature spermatozoa and mediates binding to immobilized activated C3. Biol Reprod 2004; 71: 1374-1383.
18. Holers VM, Kinoshita T, Molina H. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol Today 1992; 13: 231-236.
19. Xu C, Mao D, Holers VM et al. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 2000; 287: 498-501.
20. Bao L, Wang Y, Chang A et al. Unrestricted C3 activation occurs in Crrydeficient kidneys and rapidly leads to chronic renal failure. J Am Soc Nephrol 2007; 18: 811-822.
21. Miwa T, Zhou L, Tudoran R et al. DAF/Crry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity. Mol Immunol 2007; 44: 139-146.
22. Renner B, Coleman K, Goldberg R et al. The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol 2010; 185: 3086-3094.
23. Watanabe M, Morita Y, Mizuno M et al. CD59 protects rat kidney from complement mediated injury in collaboration with crry. Kidney Int 2000; 58: 1569-1579.
24. Hori Y, Yamada K, Hanafusa N et al. Crry, a complement regulatory protein, modulates renal interstitial disease induced by proteinuria. Kidney Int 1999; 56: 2096-2106.
25. Rankin EB, Tomaszewski JE, Haase VH. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 2006; 66: 2576-2583.
26. Li B, Sallee C, Dehoff M et al. Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol 1993; 151: 4295-4305.
27. Thurman JM, Ljubanovia D, Royer PA et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 2006; 116: 357.
28. Christensen EI, Gliemann J, Moestrup SK. Renal tubule gp330 is a calcium binding receptor for endocytic uptake of protein. J Histochem Cytochem 1992; 40: 1481-1490.
29. Lundgren S, Carling T, Hjalm G et al. Tissue distribution of human gp330/ megalin, a putative Ca(2)-sensing protein. J Histochem Cytochem 1997; 45: 383-392.
30. Ruseva MM, Hughes TR, Donev RM et al. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. Mol Immunol 2009; 46: 803-811.
31. Wu X, Spitzer D, Mao D et al. Membrane protein Crry maintains homeostasis of the complement system. J Immunol 2008; 181: 2732-2740.
32. Nomura A, Nishikawa K, Yuzawa Y et al. Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement. J Clin Invest 1995; 96: 2348-2356.
33. Miwa T, Zhou L, Kimura Y et al. Complement-dependent T cell lymphopenia caused by thymocyte deletion of the membrane complement regulator Crry. Blood 2009; 113: 2684-2694.
34. Barata L, Miwa T, Sato S et al. Deletion of Crry and DAF on murine platelets stimulates thrombopoiesis and increases factor H-dependent resistance of peripheral platelets to complement attack. J Immunol 2013; 190: 2886-2895.
35. Yamada K, Miwa T, Liu J et al. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 2004; 172: 3869-3875.
36. Renner B, Ferreira VP, Cortes C et al. Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int 2011; 80: 165-173.
37. Zaferani A, Vives RR, van der Pol P et al. Factor h and properdin recognize different epitopes on renal tubular epithelial heparan sulfate. J Biol Chem 2012; 287: 31471-31481.
38. Miwa T, Sato S, Gullipalli D et al. Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemiareperfusion injury in decay-accelerating factor and CD59 doubleknockout mice. J Immunol 2013; 190: 3552-3559.
39. Lesher AM, Zhou L, Kimura Y et al. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulopathy. J Am Soc Nephrol 2013; 24: 53-65.
40. Ruseva MM, Vernon KA, Lesher AM et al. Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency. J Am Soc Nephrol 2013; 24: 43-52.
41. Lesher AM, Nilsson B, Song WC. Properdin in complement activation and tissue injury. Mol Immunol 2013; 56: 191-198.
42. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005; 14: 703-712.
43. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844-1859.
44. Hepburn NJ, Chamberlain-Banoub JL, Williams AS et al. Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo. Mol Immunol 2008; 45: 395-405.
45. Paul MS, Aegerter M, Cepek K et al. The murine complement receptor gene family. III. The genomic and transcriptional complexity of the Crry and Crry-ps genes. J Immunol 1990; 144: 1988-1996.
46. De Vries B, Matthijsen RA, Wolfs TG et al. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation 2003; 75: 375-382.
47. Farrar CA, Zhou W, Lin T et al. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J 2006; 20: 217-226.